• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

粪便免疫化学试验选择:OC-Sensor 与 HM-JACKarc 的比较,用于评估结直肠癌高危患者。

Choice of faecal immunochemical test matters: comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal cancer.

机构信息

Eastern Hub, Bowel Cancer Screening Programme, A Floor West Block, QMC Campus, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Division of Cancer and Stem Cells, School of Medicine, Room W/D3, D Floor, West Block, Queen's Medical Centre, Nottingham, UK.

出版信息

Clin Chem Lab Med. 2020 Oct 29;59(4):721-728. doi: 10.1515/cclm-2020-1170. Print 2021 Mar 26.

DOI:10.1515/cclm-2020-1170
PMID:33112776
Abstract

OBJECTIVES

Currently, NICE recommends the use of faecal immunochemical test (FIT) at faecal haemoglobin concentrations (f-Hb) of 10 μg Hb/g faeces to stratify for colorectal cancer (CRC) risk in symptomatic populations. This f-Hb cut-off is advised across all analysers, despite the fact that a direct comparison of analyser performance, in a clinical setting, has not been performed.

METHODS

Two specimen collection devices (OC-Sensor, OC-S; HM-JACKarc, HM-J) were sent to 914 consecutive individuals referred for follow up due to their increased risk of CRC. Agreement of f-Hb around cut-offs of 4, 10 and 150 µg Hb/g faeces and CRC detection rates were assessed. Two OC-S devices were sent to a further 114 individuals, for within test comparisons.

RESULTS

A total of 732 (80.1%) individuals correctly completed and returned two different FIT devices, with 38 (5.2%) CRCs detected. Median f-Hb for individuals diagnosed with and without CRC were 258.5 and 1.8 µg Hb/g faeces for OC-S and 318.1 and 1.0 µg Hb/g faeces for HM-J respectively. Correlation of f-Hb results between OC-S/HM-J over the full range was rho=0.74, p<0.001. Using a f-Hb of 4 µg Hb/g faeces for both tests found an agreement of 88.1%, at 10 µg Hb/g faeces 91.7% and at 150 µg Hb/g faeces 96.3%. A total of 114 individuals completed and returned two OC-S devices; correlation across the full range was rho=0.98, p<0.001.

CONCLUSIONS

We found large variations in f-Hb when different FIT devices were used, but a smaller variation when the same FIT device was used. Our data suggest that analyser-specific f-Hb cut-offs are applied with regard to clinical decision making, especially at lower f-Hb.

摘要

目的

目前,NICE 建议在粪便血红蛋白浓度(f-Hb)为 10μg Hb/g 粪便时使用粪便免疫化学测试(FIT)对有症状人群进行结直肠癌(CRC)风险分层。尽管尚未在临床环境中直接比较分析器的性能,但建议在所有分析器上使用此 f-Hb 截止值。

方法

将两种标本采集装置(OC-Sensor,OC-S;HM-JACKarc,HM-J)发送给 914 名因 CRC 风险增加而接受随访的连续个体。评估了 f-Hb 在 4、10 和 150μg Hb/g 粪便的截止值周围的一致性和 CRC 检出率。将两个 OC-S 装置发送给另外 114 名个体进行内部测试比较。

结果

共有 732 名(80.1%)个体正确完成并返回了两个不同的 FIT 装置,其中检出 38 例(5.2%)CRC。诊断为 CRC 和无 CRC 的个体的中位 f-Hb 分别为 OC-S 的 258.5 和 1.8μg Hb/g 粪便,HM-J 的 318.1 和 1.0μg Hb/g 粪便。OC-S/HM-J 之间在全范围内的 f-Hb 结果相关性为 rho=0.74,p<0.001。对于两种测试,使用 4μg Hb/g 粪便的 f-Hb 发现一致性为 88.1%,使用 10μg Hb/g 粪便的 f-Hb 发现一致性为 91.7%,使用 150μg Hb/g 粪便的 f-Hb 发现一致性为 96.3%。共有 114 名个体完成并返回了两个 OC-S 装置;在全范围内的相关性为 rho=0.98,p<0.001。

结论

我们发现使用不同的 FIT 装置时 f-Hb 有很大差异,但使用相同的 FIT 装置时差异较小。我们的数据表明,特别是在 f-Hb 较低的情况下,分析器特异性 f-Hb 截止值应用于临床决策。

相似文献

1
Choice of faecal immunochemical test matters: comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal cancer.粪便免疫化学试验选择:OC-Sensor 与 HM-JACKarc 的比较,用于评估结直肠癌高危患者。
Clin Chem Lab Med. 2020 Oct 29;59(4):721-728. doi: 10.1515/cclm-2020-1170. Print 2021 Mar 26.
2
Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care.基于初级保健转介的有症状患者粪便血红蛋白浓度的结肠镜检查对结直肠癌的检出率。
Colorectal Dis. 2021 Jul;23(7):1615-1621. doi: 10.1111/codi.15405. Epub 2020 Nov 1.
3
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.基于愈创木脂的粪便潜血试验与粪便免疫化学试验用于一般风险人群结直肠癌筛查。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2.
4
Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.粪便免疫化学检测用于在初级保健中对有下腹部症状的患者进行分流,以确定是否需要转诊疑似结直肠癌患者:一项系统评价和成本效益分析。
Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330.
5
Faecal haemoglobin concentration thresholds for reassurance and urgent investigation for colorectal cancer based on a faecal immunochemical test in symptomatic patients in primary care.基于粪便免疫化学试验在初级保健中有症状患者中用于结直肠癌的确认和紧急调查的粪便血红蛋白浓度阈值。
Ann Clin Biochem. 2021 May;58(3):211-219. doi: 10.1177/0004563220985547. Epub 2021 Jan 21.
6
Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.粪便血红蛋白可定义结直肠腺瘤性息肉患者在结直肠肿瘤筛查中风险。
United European Gastroenterol J. 2020 Jun;8(5):559-566. doi: 10.1177/2050640620913674. Epub 2020 Mar 16.
7
A comparison of the faecal haemoglobin concentrations and diagnostic accuracy in patients suspected with colorectal cancer and serious bowel disease as reported on four different faecal immunochemical test systems.比较四种不同粪便免疫化学检测系统报告的疑似结直肠癌和严重肠道疾病患者的粪便血红蛋白浓度和诊断准确性。
Clin Chem Lab Med. 2022 Jun 1;60(8):1278-1286. doi: 10.1515/cclm-2021-1248. Print 2022 Jul 26.
8
Appraisal of the faecal haemoglobin, age and sex test (FAST) score in assessment of patients with lower bowel symptoms: an observational study.粪便血红蛋白、年龄和性别检测(FAST)评分在评估下消化道症状患者中的应用评价:一项观察性研究。
BMC Gastroenterol. 2019 Dec 11;19(1):213. doi: 10.1186/s12876-019-1135-5.
9
Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.粪便血红蛋白浓度在 FIT 结果阴性的人群中与后续轮次的肿瘤检出率相关:意大利基于人群筛查项目的前瞻性研究。
Gut. 2020 Mar;69(3):523-530. doi: 10.1136/gutjnl-2018-318198. Epub 2019 Aug 27.
10
Use of a faecal immunochemical test for haemoglobin can aid in the investigation of patients with lower abdominal symptoms.使用粪便免疫化学检测血红蛋白有助于对下腹部症状患者进行调查。
Clin Chem Lab Med. 2016 Apr;54(4):595-602. doi: 10.1515/cclm-2015-0617.

引用本文的文献

1
External validation of the COLOFIT colorectal cancer risk prediction model in the Oxford-FIT dataset: the importance of population characteristics and clinically relevant evaluation metrics.COLOFIT结直肠癌风险预测模型在牛津粪便隐血试验(Oxford-FIT)数据集中的外部验证:人群特征和临床相关评估指标的重要性
BMC Med. 2025 Aug 27;23(1):503. doi: 10.1186/s12916-025-04339-w.
2
Variations in the Use of Faecal Immunochemical Testing (FIT) in Primary Care in England: A Population-Based Cohort of 531,735 FITs from 495,121 Patients Between 2019 and 2023.英国初级医疗中粪便免疫化学检测(FIT)使用情况的差异:基于人群的队列研究,涵盖2019年至2023年间来自495,121名患者的531,735次FIT检测
Clin Epidemiol. 2025 Jun 8;17:523-535. doi: 10.2147/CLEP.S518048. eCollection 2025.
3
COLOFIT: Development and Internal-External Validation of Models Using Age, Sex, Faecal Immunochemical and Blood Tests to Optimise Diagnosis of Colorectal Cancer in Symptomatic Patients.COLOFIT:利用年龄、性别、粪便免疫化学检测和血液检测优化有症状患者结直肠癌诊断的模型开发及内部-外部验证
Aliment Pharmacol Ther. 2025 Mar;61(5):852-864. doi: 10.1111/apt.18459. Epub 2025 Jan 7.
4
Faecal immunochemical tests for patients with symptoms suggestive of colorectal cancer: An updated systematic review and multiple-threshold meta-analysis of diagnostic test accuracy studies.针对有结直肠癌疑似症状患者的粪便免疫化学检测:诊断试验准确性研究的最新系统评价和多阈值Meta分析
Colorectal Dis. 2024 Dec 17;27(1). doi: 10.1111/codi.17255.
5
Repeat Faecal Immunochemical Testing for Colorectal Cancer Detection in Symptomatic and Screening Patients: A Systematic Review and Meta-Analysis.对有症状患者和筛查患者进行粪便免疫化学检测以筛查结直肠癌:一项系统评价和荟萃分析
Cancers (Basel). 2024 Sep 19;16(18):3199. doi: 10.3390/cancers16183199.
6
Double faecal immunochemical testing in patients with symptoms suspicious of colorectal cancer.症状可疑结直肠癌患者的双重粪便免疫化学检测。
Br J Surg. 2023 Mar 30;110(4):471-480. doi: 10.1093/bjs/znad016.
7
Role of the faecal immunochemical test in patients with risk-stratified suspected colorectal cancer symptoms: A systematic review and meta-analysis to inform the ACPGBI/BSG guidelines.粪便免疫化学检测在具有风险分层的疑似结直肠癌症状患者中的作用:一项系统评价和荟萃分析以指导英国和爱尔兰结直肠外科医师协会/英国胃肠病学会指南
Lancet Reg Health Eur. 2022 Oct 3;23:100518. doi: 10.1016/j.lanepe.2022.100518. eCollection 2022 Dec.
8
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG).疑似结直肠癌(CRC)体征或症状患者的粪便免疫化学检测(FIT):英国和爱尔兰结直肠外科学会(ACPGBI)与英国胃肠病学会(BSG)联合指南
Gut. 2022 Jul 12;71(10):1939-62. doi: 10.1136/gutjnl-2022-327985.
9
The COLO-COHORT (Colorectal Cancer Cohort) study: Protocol for a multi-centre, observational research study and development of a consent-for-contact research platform.COLO-COHORT(结直肠癌队列)研究:一项多中心观察性研究的方案及同意接触型研究平台的开发。
Colorectal Dis. 2022 Oct;24(10):1216-1226. doi: 10.1111/codi.16160. Epub 2022 Jun 3.
10
Evaluation of the Sentinel-FOB gold faecal immunochemical test for the presence of haemoglobin using the automated Roche Cobas 8000 system.使用罗氏Cobas 8000自动化系统评估Sentinel-FOB金标粪便免疫化学检测法检测血红蛋白的情况。
Pract Lab Med. 2022 Jan 15;29:e00263. doi: 10.1016/j.plabm.2022.e00263. eCollection 2022 Mar.